Hepatocellular carcinoma: an Asian perspective

Area of Science:

• Hepatology
• Oncology
• Public Health

Background:

• Hepatocellular carcinoma (HCC) is a prevalent malignancy in Asia, with incidence rates exceeding 30 cases/100,000/year.
• High prevalence of chronic hepatitis B is the primary driver of HCC in Asia.
• HCC often presents in advanced stages due to asymptomatic early development and rapid tumor growth.

Purpose of the Study:

• To review the epidemiology, risk factors, and management of Hepatocellular Carcinoma (HCC) in Asia.
• To highlight the impact of Hepatitis B vaccination on HCC incidence.
• To discuss current and future challenges in HCC treatment and prevention.

Main Methods:

• Review of epidemiological data on HCC incidence and mortality in Asia.
• Analysis of the role of chronic hepatitis B as a risk factor.
• Evaluation of current treatment modalities including hepatic resection, transarterial chemoembolization, percutaneous ethanol injection, radiofrequency ablation, and liver transplant.
• Assessment of screening program effectiveness and survival outcomes.

Main Results:

• Chronic hepatitis B is the predominant risk factor for HCC in Asia.
• Hepatitis B vaccination shows promise in reducing HCC incidence in regions with widespread vaccination programs.
• Screening programs detect earlier HCC but have not yet demonstrably improved patient survival.
• Treatment options are limited by tumor extent and underlying liver function, with poor survival rates for non-resectable tumors.

Conclusions:

• Hepatocellular carcinoma (HCC) incidence in Asia is strongly linked to chronic hepatitis B, a preventable cause through vaccination.
• Effective management requires early detection and improved therapeutic strategies, with a future focus on the premalignant stage.
• Despite advances, HCC treatment outcomes remain poor, underscoring the need for enhanced prevention and early intervention efforts.